NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
43 trialsNCT02970318 2026-02-06
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02763319 2025-07-17
B-MIND
Incyte Corporation
Phase 2/3 Completed
NCT01776840 2025-07-08
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01974440 2025-05-25
SELENE
Janssen Research & Development, LLC
Phase 3 Completed
NCT04666038 2025-04-20
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT04745832 2024-11-04
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
Phase 3 Terminated
NCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed
NCT02005471 2023-10-17
MURANO
Hoffmann-La Roche
Phase 3 Completed
NCT01596621 2023-05-26
A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT04236141 2023-03-03
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
Hoffmann-La Roche
Phase 3 Terminated
NCT02257567 2022-11-14
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT01332968 2022-08-11
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Hoffmann-La Roche
Phase 3 Completed
NCT01188681 2021-06-10
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
Aptevo Therapeutics
Phase 1/2 Completed
NCT02596971 2021-05-24
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 1/2 Completed
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT02951156 2020-12-17
Javelin DLBCL
Pfizer
Phase 3 Terminated
NCT01889069 2020-08-13
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
Hoffmann-La Roche
Phase 3 Completed
NCT01569295 2020-03-10
Tugela
Gilead Sciences
Phase 3 Completed
NCT01611090 2020-03-03
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02320487 2020-02-11
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 2 Completed
NCT02071225 2020-02-07
A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 2 Completed
NCT01059630 2020-01-13
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Genentech, Inc.
Phase 3 Completed
NCT01905943 2019-10-28
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 3 Completed
NCT02187861 2019-06-05
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
Hoffmann-La Roche
Phase 2 Completed
NCT01874054 2019-02-12
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Seagen Inc.
Phase 1/2 Completed
NCT01980888 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01732926 2018-11-16
Bridalveil
Gilead Sciences
Phase 3 Terminated
NCT01294579 2018-08-09
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Novartis
Phase 2 Completed
NCT00877006 2018-02-05
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT01724021 2018-01-23
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Hoffmann-La Roche
Phase 3 Completed
NCT01500083 2017-08-14
BENDACT
Lundbeck Canada Inc.
Phase 3 Completed
NCT01317901 2017-06-28
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Aptevo Therapeutics
Phase 1 Completed
NCT01466153 2017-05-31
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
MedImmune LLC
Phase 2 Completed
NCT01520922 2017-01-19
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis
Phase 2 Completed
NCT01088984 2016-05-23
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT01056510 2015-06-25
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
Hoffmann-La Roche
Phase 4 Completed
NCT00891839 2014-11-04
Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT01118845 2013-07-04
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
SymBio Pharmaceuticals
Phase 2 Completed
NCT00920855 2012-10-04
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT01108341 2012-08-28
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00636792 2012-01-13
VERTICAL
Millennium Pharmaceuticals, Inc.
Phase 2 Completed